2022 年 39 巻 5 号 p. 786-790
Peripheral neuropathies are very common neurological disorders that are caused by various etiologies. This review focuses on four neuropathies where substantial advances have been made recently. In Guillain–Barré syndrome, treatment for severe cases is still a challenge. Unfortunately, the efficacy of immunoglobulin re–administration has not been proven. Clinical trials of several anti–complement drugs are currently underway and results are awaited. In CIDP (chronic inflammatory demyelinating polyneuropathy), European Academy of Neurolog/Peripheral Nerve Society published updated guidelines. The classification of CIDP subtypes has been changed and autoimmune nodopathies are divided from CIDP. Subcutaneeous immunoglobulin has been added as a standard maintainace therapy. In addition, knowledge is accumulation regarding optimization of globulin dosing for maintenance therapy and the efficacy of rituximab for autoimmune nodopathies has been investigated. For ATTR amyloidosis, remarkable treatment progress has been made. In addtion to stabilizers of transthyretine, RNA interference therapeutic agents have become the main treatment. Chemotherapy induced peripheral neuropathy (CIPN) is a very common complication of anti–cancer treatment. However, no drugs have been successfully developed for CIPN treatment. Researches on new drugs such as GM1 and calmangafodipir are ongoing and non–pharmacologic interventions have been investigated. With advances in cancer treatment and the increasing number of cancer survivors, CIPN patients are increasing and future developments are expected.
